RE:RE:RE:RE:RE:RE:RE:RE:ACB interview on Midas
You make a good point about the speed to market for smaller deals. From what I've seen in the new investor deck, it looks like they want to supply the infuse2o to the partner. That would allow for quality and production control, but the practical way to scale for a larger deal is to leverage a larger partner's resources to create the extract. I'm sure they know what they're doing. I would certainly think some of the 'smaller' deals providing the extract will start flowing, probably after New Year's.